| Angiotensin I-converting enzyme (ACE) inhibitors and restenosis after coronary artery stenting in patients with the DD genotype of the ACE gene. | |
| | |
MedLine Citation:
|
PMID: 12798565 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: We tested the hypothesis that patients with the DD genotype of the angiotensin I-converting enzyme (ACE) gene who are treated with ACE inhibitors are at a higher risk of restenosis after coronary stent placement than patients who do not receive ACE inhibitors. BACKGROUND: Two recent studies with a limited series of patients carrying the DD genotype suggested an unfavorable impact of the use of ACE inhibitors on the restenotic process after implantation of stents in coronary arteries. Because these findings may question the use of ACE inhibitors after coronary stenting, we examined this important issue in a large series of patients. METHODS: We determined the ACE gene I/D genotype of 2,222 consecutive patients with symptomatic coronary artery disease who underwent stent implantation. The patients with the DD genotype (n = 612) constituted the study population. The primary end point was in-stent restenosis, which was assessed as angiographic restenosis (> or =50% diameter stenosis at six-month follow-up) and clinical restenosis (need for target vessel revascularization due to symptoms or signs of ischemia in the presence of angiographic restenosis over one year after the intervention). RESULTS: Of the 612 patients with the DD genotype, 403 (65.8%) were treated with ACE inhibitors and 209 (34.2%) did not receive ACE inhibitors. The angiographic and clinical restenosis rates were not significantly different between the group treated with ACE inhibitors and the group not receiving ACE inhibitors (p = 0.55). Continuous measures of restenosis, minimal lumen diameter, diameter stenosis, late lumen loss, and loss index were also similar in both groups (p > or = 0.55). In addition, one-year survival free of myocardial infarction was not significantly different between the two groups (p = 0.27). CONCLUSIONS: In contrast to previous reports, our study provides evidence that patients carrying the DD genotype are not exposed to an increased risk of restenosis after stent placement when treated with ACE inhibitors. |
| | |
Authors:
|
Werner Koch; Julinda Mehilli; Nicolas von Beckerath; Corinna Böttiger; Albert Schömig; Adnan Kastrati |
Related Documents
:
|
1552115 - Lumen narrowing after percutaneous transluminal coronary balloon angioplasty follows a ... 17607535 - Drug-eluting stents, restenosis and revascularization. 10212495 - Radioactive stents. 16019615 - Provisional stenting for multivessel pci. 3622035 - Current practice patterns in the management of acute myocardial infarction. survey of t... 18839405 - Percutaneous ultrasound-guided stenting of the atrial septum in fetal sheep. |
Publication Detail:
|
Type: Comparative Study; Journal Article |
Journal Detail:
|
Title: Journal of the American College of Cardiology Volume: 41 ISSN: 0735-1097 ISO Abbreviation: J. Am. Coll. Cardiol. Publication Date: 2003 Jun |
Date Detail:
|
Created Date: 2003-06-11 Completed Date: 2003-07-18 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8301365 Medline TA: J Am Coll Cardiol Country: United States |
Other Details:
|
Languages: eng Pagination: 1957-61 Citation Subset: AIM; IM |
Affiliation:
|
Deutsches Herzzentrum München, Experimentelle Kardiologie, Technische Universität München, Lazarettstrasse 36, D-80636 Munich, Germany. wkoch@dhm.mhn.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Angiotensin-Converting Enzyme Inhibitors / therapeutic use* Blood Vessel Prosthesis Implantation Coronary Angiography Coronary Artery Disease / enzymology*, genetics, therapy* Coronary Restenosis / enzymology*, genetics, therapy* Disease-Free Survival Endpoint Determination Female Follow-Up Studies Genetic Markers / drug effects, genetics Genotype Humans Incidence Male Middle Aged Peptidyl-Dipeptidase A / genetics* Stents* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin-Converting Enzyme Inhibitors; 0/Genetic Markers; EC 3.4.15.1/Peptidyl-Dipeptidase A |
| Comments/Corrections | |
Comment In:
|
J Am Coll Cardiol. 2003 Jun 4;41(11):1962-3
[PMID:
12798566
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Poverty, process of care, and outcome in acute coronary syndromes.
Next Document: Percutaneous transvenous cellular cardiomyoplasty. A novel nonsurgical approach for myocardial cell ...